{"id":"https://openalex.org/W3000494396","doi":"https://doi.org/10.1002/cpt.1794","title":"Data Integrity in Global Clinical Trials: Discussions From Joint US Food and Drug Administration and UK Medicines and Healthcare Products Regulatory Agency Good Clinical Practice Workshop","display_name":"Data Integrity in Global Clinical Trials: Discussions From Joint US Food and Drug Administration and UK Medicines and Healthcare Products Regulatory Agency Good Clinical Practice Workshop","publication_year":2020,"publication_date":"2020-01-20","ids":{"openalex":"https://openalex.org/W3000494396","doi":"https://doi.org/10.1002/cpt.1794","mag":"3000494396","pmid":"https://pubmed.ncbi.nlm.nih.gov/31958142"},"language":"en","primary_location":{"id":"doi:10.1002/cpt.1794","doi":"https://doi.org/10.1002/cpt.1794","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpt.1794","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"public-domain","license_id":"https://openalex.org/licenses/public-domain","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5008688155","display_name":"Ni A. Khin","orcid":"https://orcid.org/0009-0004-3224-4728","observed_orcids":["https://orcid.org/0009-0004-3224-4728"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ni A. Khin","raw_affiliation_strings":["Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5077252866","display_name":"Gail Francis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282191","display_name":"Medicines and Healthcare products Regulatory Agency","ror":"https://ror.org/05fan1e59","country_code":"GB","type":"government","lineage":["https://openalex.org/I4405282191"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Gail Francis","raw_affiliation_strings":["Inspection, Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inspection, Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK","institution_ids":["https://openalex.org/I4405282191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5047208152","display_name":"Jean Mulinde","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jean Mulinde","raw_affiliation_strings":["Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5064899242","display_name":"Cheryl\u00a0A. Grandinetti","orcid":"https://orcid.org/0009-0003-5861-8962","observed_orcids":["https://orcid.org/0009-0003-5861-8962"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cheryl Grandinetti","raw_affiliation_strings":["Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5062525539","display_name":"Rachel Skeete","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rachel Skeete","raw_affiliation_strings":["Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080653038","display_name":"Bei Yu","orcid":"https://orcid.org/0000-0001-5425-0011","observed_orcids":["https://orcid.org/0000-0001-5425-0011"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Bei Yu","raw_affiliation_strings":["Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020119019","display_name":"Kassa Ayalew","orcid":"https://orcid.org/0000-0002-4613-1706","observed_orcids":["https://orcid.org/0000-0002-4613-1706"]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kassa Ayalew","raw_affiliation_strings":["Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5075388650","display_name":"Seongeun\u2010Julia Cho","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Seongeun\u2010Julia Cho","raw_affiliation_strings":["Division of Generic Drug Bioequivalence Evaluation, Office of Study Integrity and Surveillance (OSIS), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Generic Drug Bioequivalence Evaluation, Office of Study Integrity and Surveillance (OSIS), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024459438","display_name":"Andrew W. Fisher","orcid":"https://orcid.org/0000-0001-9298-1253","observed_orcids":["https://orcid.org/0000-0001-9298-1253"]},"institutions":[{"id":"https://openalex.org/I4405282191","display_name":"Medicines and Healthcare products Regulatory Agency","ror":"https://ror.org/05fan1e59","country_code":"GB","type":"government","lineage":["https://openalex.org/I4405282191"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Andrew Fisher","raw_affiliation_strings":["Inspection, Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inspection, Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK","institution_ids":["https://openalex.org/I4405282191"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068715022","display_name":"Cynthia Kleppinger","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cynthia Kleppinger","raw_affiliation_strings":["Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5042008371","display_name":"Ruben C. Ayala","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ruben Ayala","raw_affiliation_strings":["Division of New Drug Bioequivalence Evaluation, Office of Study Integrity and Surveillance (OSIS), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of New Drug Bioequivalence Evaluation, Office of Study Integrity and Surveillance (OSIS), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015650171","display_name":"Charles R. Bonapace","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Charles Bonapace","raw_affiliation_strings":["Division of New Drug Bioequivalence Evaluation, Office of Study Integrity and Surveillance (OSIS), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of New Drug Bioequivalence Evaluation, Office of Study Integrity and Surveillance (OSIS), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Arindam Dasgupta","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arindam Dasgupta","raw_affiliation_strings":["Division of New Drug Bioequivalence Evaluation, Office of Study Integrity and Surveillance (OSIS), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of New Drug Bioequivalence Evaluation, Office of Study Integrity and Surveillance (OSIS), Office of Translational Sciences (OTS), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028546110","display_name":"Phillip D. Kronstein","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1320320070","display_name":"United States Food and Drug Administration","ror":"https://ror.org/034xvzb47","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070"]},{"id":"https://openalex.org/I1333606569","display_name":"Center for Drug Evaluation and Research","ror":"https://ror.org/00yf3tm42","country_code":"US","type":"facility","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Phillip D. Kronstein","raw_affiliation_strings":["Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Clinical Compliance Evaluation, Office of Scientific Investigations (OSI), Office of Compliance, Center for Drug Evaluation and Research (CDER), US Food and Drug Administration (FDA), Silver Spring, Maryland, USA","institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5079593795","display_name":"Stephen Vinter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405282191","display_name":"Medicines and Healthcare products Regulatory Agency","ror":"https://ror.org/05fan1e59","country_code":"GB","type":"government","lineage":["https://openalex.org/I4405282191"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"Stephen Vinter","raw_affiliation_strings":["Inspection, Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Inspection, Enforcement and Standards Division, Medicines and Healthcare Products Regulatory Agency (MHRA), London, UK","institution_ids":["https://openalex.org/I4405282191"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5008688155"],"corresponding_institution_ids":["https://openalex.org/I1320320070","https://openalex.org/I1333606569"],"apc_list":{"value":3000,"currency":"USD","value_usd":3000},"apc_paid":null,"fwci":2.4344,"has_fulltext":false,"cited_by_count":30,"citation_normalized_percentile":{"value":0.89236177,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":93,"max":99},"biblio":{"volume":"108","issue":"5","first_page":"949","last_page":"963"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10582","display_name":"Ethics in Clinical Research","score":0.33009999990463257,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10582","display_name":"Ethics in Clinical Research","score":0.33009999990463257,"subfield":{"id":"https://openalex.org/subfields/2739","display_name":"Public Health, Environmental and Occupational Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11649","display_name":"Pharmaceutical industry and healthcare","score":0.20340000092983246,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T13417","display_name":"Biomedical Ethics and Regulation","score":0.08649999648332596,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/data-integrity","display_name":"data integrity","score":0.828000009059906},{"id":"https://openalex.org/keywords/good-clinical-practice","display_name":"good clinical practice","score":0.875},{"id":"https://openalex.org/keywords/clinical-trial-data-quality","display_name":"clinical trial data quality","score":0.6259999871253967},{"id":"https://openalex.org/keywords/regulatory-inspection","display_name":"regulatory inspection","score":0.6340000033378601},{"id":"https://openalex.org/keywords/audit-trail","display_name":"audit trail","score":0.9800000190734863},{"id":"https://openalex.org/keywords/bias-in-clinical-trials","display_name":"bias in clinical trials","score":0.7870000004768372},{"id":"https://openalex.org/keywords/global-clinical-trials","display_name":"global clinical trials","score":0.753000020980835},{"id":"https://openalex.org/keywords/fda","display_name":"FDA","score":0.41200000047683716},{"id":"https://openalex.org/keywords/medicines-and-healthcare-products-regulatory-agency","display_name":"MHRA","score":0.8389999866485596},{"id":"https://openalex.org/keywords/regulatory-perspectives","display_name":"regulatory perspectives","score":0.3779999911785126}],"concepts":[{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.7155792713165283},{"id":"https://openalex.org/C3018890749","wikidata":"https://www.wikidata.org/wiki/Q204711","display_name":"Food and drug administration","level":2,"score":0.6360659599304199},{"id":"https://openalex.org/C2778150722","wikidata":"https://www.wikidata.org/wiki/Q1537519","display_name":"Good clinical practice","level":3,"score":0.6025065779685974},{"id":"https://openalex.org/C108170787","wikidata":"https://www.wikidata.org/wiki/Q3951828","display_name":"Agency (philosophy)","level":2,"score":0.5612725615501404},{"id":"https://openalex.org/C2771230","wikidata":"https://www.wikidata.org/wiki/Q4926699","display_name":"Blinding","level":3,"score":0.544925332069397},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5401247143745422},{"id":"https://openalex.org/C199521495","wikidata":"https://www.wikidata.org/wiki/Q181487","display_name":"Audit","level":2,"score":0.5289884805679321},{"id":"https://openalex.org/C160735492","wikidata":"https://www.wikidata.org/wiki/Q31207","display_name":"Health care","level":2,"score":0.5088484287261963},{"id":"https://openalex.org/C3019398576","wikidata":"https://www.wikidata.org/wiki/Q1639780","display_name":"Regulatory agency","level":2,"score":0.4770221710205078},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.47044768929481506},{"id":"https://openalex.org/C2780511413","wikidata":"https://www.wikidata.org/wiki/Q18749628","display_name":"Regulatory affairs","level":2,"score":0.47015950083732605},{"id":"https://openalex.org/C2779530757","wikidata":"https://www.wikidata.org/wiki/Q1207505","display_name":"Quality (philosophy)","level":2,"score":0.4562036991119385},{"id":"https://openalex.org/C2779709869","wikidata":"https://www.wikidata.org/wiki/Q1292017","display_name":"Good manufacturing practice","level":3,"score":0.41027164459228516},{"id":"https://openalex.org/C144133560","wikidata":"https://www.wikidata.org/wiki/Q4830453","display_name":"Business","level":0,"score":0.4095888137817383},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.2662678360939026},{"id":"https://openalex.org/C17744445","wikidata":"https://www.wikidata.org/wiki/Q36442","display_name":"Political science","level":0,"score":0.22505584359169006},{"id":"https://openalex.org/C3116431","wikidata":"https://www.wikidata.org/wiki/Q31728","display_name":"Public administration","level":1,"score":0.20861095190048218},{"id":"https://openalex.org/C121955636","wikidata":"https://www.wikidata.org/wiki/Q4116214","display_name":"Accounting","level":1,"score":0.20547083020210266},{"id":"https://openalex.org/C199539241","wikidata":"https://www.wikidata.org/wiki/Q7748","display_name":"Law","level":1,"score":0.10227736830711365},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C138885662","wikidata":"https://www.wikidata.org/wiki/Q5891","display_name":"Philosophy","level":0,"score":0.0},{"id":"https://openalex.org/C111472728","wikidata":"https://www.wikidata.org/wiki/Q9471","display_name":"Epistemology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000068598","descriptor_name":"Data Accuracy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000079803","descriptor_name":"Data Management","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D002986","descriptor_name":"Clinical Trials as Topic","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D003625","descriptor_name":"Data Collection","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":false},{"descriptor_ui":"D005060","descriptor_name":"Europe","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012107","descriptor_name":"Research Design","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":true},{"descriptor_ui":"D014481","descriptor_name":"United States","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014486","descriptor_name":"United States Food and Drug Administration","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D015337","descriptor_name":"Multicenter Studies as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016494","descriptor_name":"Computer Security","qualifier_ui":"Q000592","qualifier_name":"standards","is_major_topic":false},{"descriptor_ui":"D017277","descriptor_name":"Drug Approval","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1002/cpt.1794","doi":"https://doi.org/10.1002/cpt.1794","is_oa":false,"landing_page_url":"https://doi.org/10.1002/cpt.1794","pdf_url":null,"source":{"id":"https://openalex.org/S159852663","display_name":"Clinical Pharmacology & Therapeutics","issn_l":"0009-9236","issn":["0009-9236","1085-8733","1532-6535"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":"public-domain","license_id":"https://openalex.org/licenses/public-domain","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical Pharmacology & Therapeutics","raw_type":"journal-article"},{"id":"pmid:31958142","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/31958142","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Clinical pharmacology and therapeutics","raw_type":"Conference Proceedings"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.4043000042438507}],"sustainable_development_goals_aurora":[{"id":"https://metadata.un.org/sdg/17","display_name":"Partnerships for the goals","score":0.46000000834465027}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":10,"referenced_works":["https://openalex.org/W1995279104","https://openalex.org/W2007233978","https://openalex.org/W2017527474","https://openalex.org/W2031158571","https://openalex.org/W2039787467","https://openalex.org/W2060413967","https://openalex.org/W2065624329","https://openalex.org/W2101454487","https://openalex.org/W2339055359","https://openalex.org/W2896044978"],"related_works":["https://openalex.org/W2155846571","https://openalex.org/W2127499025","https://openalex.org/W147395029","https://openalex.org/W2276753051","https://openalex.org/W4234293980","https://openalex.org/W3134968736","https://openalex.org/W2008015261","https://openalex.org/W7126256219","https://openalex.org/W2045904193","https://openalex.org/W2134364418"],"abstract_inverted_index":{"Good":[0],"Clinical":[1],"Practice":[2],"(GCP)":[3],"is":[4],"an":[5],"international":[6],"ethical":[7],"and":[8,16,35,67,75,78,83,94,120],"scientific":[9],"quality":[10,104],"standard":[11],"for":[12,72],"designing,":[13],"conducting,":[14],"recording,":[15],"reporting":[17],"clinical":[18,33,49,132],"trials.":[19],"Regulatory":[20,86,110],"agencies":[21,142],"conduct":[22],"GCP":[23,61],"inspections":[24],"to":[25,36,46,54,115],"verify":[26],"the":[27,38,55,64,79,96,100,121],"integrity":[28,129],"of":[29,40,63,102,118,123,140],"data":[30,103,108,113,128],"generated":[31],"in":[32,44,91,126,130],"trials":[34,50,133],"assure":[37],"protection":[39],"human":[41],"research":[42],"subjects,":[43],"addition":[45],"ensuring":[47],"that":[48],"are":[51],"conducted":[52],"according":[53],"applicable":[56],"regulations.":[57],"The":[58],"first":[59],"joint":[60],"workshop":[62],"US":[65],"Food":[66],"Drug":[68,73],"Administration":[69],"(FDA)":[70],"Center":[71],"Evaluation":[74],"Research":[76],"(CDER)":[77],"United":[80],"Kingdom":[81],"Medicines":[82],"Healthcare":[84],"products":[85],"Agency":[87],"(MHRA-UK)":[88],"was":[89],"held":[90],"October":[92],"2018":[93],"provided":[95],"agencies'":[97],"perspectives":[98,111],"on":[99,107,112,143],"importance":[101],"management":[105],"practices":[106],"integrity.":[109],"blinding":[114],"minimize":[116],"introduction":[117],"bias,":[119],"role":[122],"audit":[124],"trails":[125],"assessing":[127],"global":[131],"were":[134],"discussed.":[135],"This":[136],"paper":[137],"summarizes":[138],"considerations":[139],"both":[141],"these":[144],"topics,":[145],"along":[146],"with":[147],"case":[148],"examples.":[149]},"counts_by_year":[{"year":2026,"cited_by_count":6},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":6},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":8},{"year":2021,"cited_by_count":3}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2020-01-23T00:00:00"}